Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al.
JSON
von Meijenfeldt FA, Havervall S, Adelmeijer J, Thalin C, Lisman T
J Thromb Haemost 20 (1) 267-269 [2022-01-00; online 2021-11-22]
To the Editor: With great interest we read the recent brief report by dr. Fogarty and colleagues providing evidence for persistent endothelial cell activation in convalescent COVID-19 patients [1]. The authors showed that plasma levels of von Willebrand factor (VWF), factor VIII, and soluble thrombomodulin were elevated at a median of 68 days after initial COVID-19 symptom resolution or discharge from the hospital. Interestingly, not all these patients experienced severe disease. Levels of endothelial injury markers were associated with long-term symptoms, including dyspnoea, fatigue and concentration impairment, often referred to as long COVID.
PubMed 34731533
DOI 10.1111/jth.15580
Crossref 10.1111/jth.15580